Key result
Plasma biomarkers outperform retinal parameters for detecting moderate cognitive impairment with an AUC of ~0.76.
Why the study?
Accurate and early diagnosis of Alzheimer's disease and vascular dementia is crucial for enabling timely interventions and improving patient outcomes.
Do plasma biomarkers and optical coherence tomography (OCT) parameters accurately identify moderate cognitive impairment and dementia in older adults?
Cross-Sectional (n=509)
Do plasma biomarkers and optical coherence tomography (OCT) parameters accurately identify moderate cognitive impairment and dementia in older adults?
Plasma biomarkers, particularly neurofilament light chain, offer superior diagnostic accuracy for identifying moderate cognitive decline and dementia compared to retinal OCT parameters.
Answers are grounded in this paper and cite their sources.
Plasma biomarkers may aid cognitive staging in memory clinics; leaves open prospective validation against retinal OCT before practice change.
Accurate and early diagnosis of Alzheimer's disease and vascular dementia is crucial for enabling timely interventions and improving patient outcomes. This study evaluates the diagnostic performance of plasma biomarkers (neurofilament light chain and phosphorylated tau181) and retinal biomarkers (retinal nerve fibre layer and ganglion cell-inner plexiform layer), individually and in combination, in differentiating moderate cognitive impairment and dementia from mild cognitive impairment and no cognitive impairment. A cross-sectional study was conducted involving 509 participants, aged 50 and older, recruited from a memory clinic. The participants were categorized as normal (n = 100), mild cognitive impairment (n = 144), moderate cognitive impairment (n = 90) or dementia (n = 175) based on detailed clinical assessments, neuropsychological testing and MRI scans. The thickness of the ganglion cell-inner plexiform layer (P < 0.001) and retinal nerve fibre layer (P = 0.030) decreased progressively from normal cognition to cognitive impairment and dementia. The thickest layers were observed in individuals with no cognitive impairment (mean ± standard deviation: ganglion cell-inner plexiform layer: 76 ± 11 µm, retinal nerve fibre layer: 92 ± 10 µm), while the thinnest layers were found in individuals with dementia (ganglion cell-inner plexiform layer: 72 ± 14 µm, retinal nerve fibre layer: 89 ± 12 µm). Plasma biomarker levels increased progressively from normal cognition to cognitive impairment and dementia (P < 0.001). Levels were lowest in individuals with no cognitive impairment [median (interquartile range): neurofilament light chain: 15 (9) pg/mL, phosphorylated tau181: 1.85 (1.00) pg/mL] and highest in those with dementia [neurofilament light chain: 34 (27) pg/mL, phosphorylated tau181: 3.24 (2.81) pg/mL]. After adjusting for retinal scan signal strength, neurofilament light chain showed a stronger negative association with retinal nerve fibre layer thickness [standardized beta estimate (β) = −0.184] and ganglion cell-inner plexiform layer thickness (β = −0.139) compared to phosphorylated tau181, which exhibited weaker associations with ganglion cell-inner plexiform layer (β = −0.091) and retinal nerve fibre layer (β = −0.059). While retinal parameters provided modest discriminatory ability (AUC = 0.60), plasma biomarkers demonstrated superior diagnostic performance (AUC = 0.76). Notably, neurofilament light chain had a stronger association with retinal thinning than phosphorylated tau181 and offered superior diagnostic value for identifying moderate cognitive decline. These findings underscore the potential of plasma biomarkers, particularly neurofilament light chain, for the early detection of dementia.
No takes yet. Share an insight, caveat, or question.
Jali et al. (2024) conducted a cross-sectional in Cognitive impairment and dementia (n=509). Plasma biomarkers (neurofilament light chain and phosphorylated tau181) and retinal biomarkers (retinal nerve fibre layer and ganglion cell-inner plexiform layer) vs. Mild cognitive impairment and no cognitive impairment was evaluated on Diagnostic accuracy for differentiating moderate cognitive impairment/dementia from mild cognitive impairment/no cognitive impairment (AUC 0.76 for combined plasma biomarkers, 95% CI 0.71-0.80, p=<0.001). Plasma biomarkers demonstrated superior diagnostic performance (AUC 0.76) compared to retinal parameters (AUC 0.60) in differentiating moderate cognitive impairment and dementia from mild or no impairment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: